Eli Lilly rose more than 3% to $1024.5. According to the news, Lilly released a statement saying that patients receiving the highest dose of retaglutide lost more than 23% of their weight within 68 weeks. According to the results of the patient's self-completed questionnaire, the degree of relief from knee pain of the study participants was over 62%. Wall Street had previously predicted that the test's weight loss data range was about 20% to 23%, and the knee pain relief would reach at least 50%. Eli Lilly said that the results of this trial exceeded market expectations, and some patients chose to withdraw from the clinical trial because the weight loss effect was too obvious.

Eli Lilly rose more than 3% to $1024.5. According to the news, Lilly released a statement saying that patients receiving the highest dose of retaglutide lost more than 23% of their weight within 68 weeks. According to the results of the patient's self-completed questionnaire, the degree of relief from knee pain of the study participants was over 62%. Wall Street had previously predicted that the test's weight loss data range was about 20% to 23%, and the knee pain relief would reach at least 50%. Eli Lilly said that the results of this trial exceeded market expectations, and some patients chose to withdraw from the clinical trial because the weight loss effect was too obvious.